within Pharmacolibrary.Drugs.ATC.L;

model L01FD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.011333333333333334,
    adminDuration  = 600,
    adminMass      = 0.0036,
    adminCount     = 1,
    Vd             = 0.00313,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1. It is used primarily for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane. It is an FDA- and EMA-approved therapy for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adult female patients with HER2-positive metastatic breast cancer, based on published population PK study.</p><h4>References</h4><ol><li><p>Okamoto, H, et al., &amp; Kuga, H (2020). Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 50(10) 1242–1250. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2020.1755909&quot;>10.1080/00498254.2020.1755909</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32306807/&quot;>https://pubmed.ncbi.nlm.nih.gov/32306807</a></p></li><li><p>Tamura, K, et al., &amp; Modi, S (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>The Lancet. Oncology</i> 20(6) 816–826. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(19)30097-X&quot;>10.1016/S1470-2045(19)30097-X</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31047803/&quot;>https://pubmed.ncbi.nlm.nih.gov/31047803</a></p></li><li><p>Diéras, V, &amp; Bachelot, T (2014). The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. <i>Targeted oncology</i> 9(2) 111–122. DOI:<a href=&quot;https://doi.org/10.1007/s11523-013-0287-4&quot;>10.1007/s11523-013-0287-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23852665/&quot;>https://pubmed.ncbi.nlm.nih.gov/23852665</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FD03;
